The Supporting online information files contain all of the omics results from our study. Raw data files from proteomics, metabolomics and lipidomics experiments and search results files can be obtained by downloading the files from the PRIDE ProteomeXchange data repository (<http://www.proteomexchange.org/>) with project accession number PXD007646.

Introduction {#sec001}
============

Over the last two decades, mass spectrometry has been used extensively to characterize the protein and small molecule content in biological samples \[[@pone.0186258.ref001]\]. Mass spectrometry including gas chromatography and liquid chromatography has been used extensively to profile molecules in urine, both from animals and humans \[[@pone.0186258.ref002], [@pone.0186258.ref003]\]. Methods have been developed and evaluated for preparing horse urine samples for small molecule analysis including precipitation and liquid-liquid extraction methods \[[@pone.0186258.ref004]\]. High resolution mass spectrometry and speed of fragmentation scanning has allowed proteins to be profiled from many diseases tissues and mammalian proteomes including relative protein levels and post-translational modifications of proteins \[[@pone.0186258.ref001], [@pone.0186258.ref005]--[@pone.0186258.ref007]\]. In addition, lipidomics profiling has recently become popular in present day---omics technologies using mass spectrometry (MS) \[[@pone.0186258.ref008]\]. The tri-ome (proteomics, metabolomics and lipidomics) has been studied by our group from human cell lines in diseases such as cancer as well as mouse tumor tissues \[[@pone.0186258.ref009]\]. The tri-ome can reveal active pathways that are driving the biology of the organism or tissue in question at the point in time of sampling. Information can be obtained from metabolic pathways, protein synthesis and expression, signal transduction and fatty acid biosynthesis. When studying biofluids such as urine or blood serum, one can also garner information about secreted molecules that are indicative of external influences or internal influences on an organism's biological state. Equine urine has been tested for several decades in the performance horse industry for the presence of drugs and illegal substances in the racing, showing, eventing and Olympic industries using both GC-MS and LC-MS \[[@pone.0186258.ref010]--[@pone.0186258.ref029]\]. However, one can also begin to think about profiling the widely accessible fluid for performance markers or measures of health. A recent article utilized a multi-omics proteomic and metabolomic strategy to probe urinary diseases \[[@pone.0186258.ref030]\]. In this study, we incorporate a "serial-omics" or triomics approach to help create a baseline of normal horse urine in terms of its protein, metabolite and lipid content for the potential diagnosis, treatment and prevention of equine diseases. It uses four different LC-MS/MS platforms including targeted metabolomics, untargeted metabolomics, untargeted lipidomics and untargeted proteomics including phosphoproteomics. The requirement of all platforms is that there is fragmentation to support chemical structure and amino acid sequence with the help of commercial software and publicly available databases for their identification. JF Sierra Flame is an American Quarter Horse Association (AQHA) registered mare foaled in May, 2004. She is fed a daily diet of primarily forage (\~20--22 lb) with 2 cups of a fortified grain pellet supplement containing protein, vitamins, minerals, probiotics, etc. in addition to occasional feeding of natural treats such as apples and/or carrots. She is ridden approximately three times per week and has access to a pasture containing grass and some weeds. On rare occasion, if soreness is suspected, the horse is fed Bute-Less pellets (Absorbine) containing the natural anti-inflammatory herbs Devil's claw and Yucca extract. This study represents molecules that we could accurately detect in horse urine sample using various mass spectrometry approaches that are common to our laboratory and some may be potentially used as biomarkers with rigorous testing.

Material and methods {#sec002}
====================

Liquid-liquid extraction {#sec003}
------------------------

\~45 mL of horse mare urine was collected in mid-stream using a 50 mL polypropylene tube. A 333 μL aliquot of horse urine was taken and 2.475 mL HPLC grade methanol (Pharmco-Aaper, \#33900HPLC) was added and vortexed vigorously for 1 min. After the addition of 8.25 mL of 99.8% MTBE (Sigma Aldrich, \#306975-1L), the samples were shaken for 1 hr at RT. We added 2.06 mL of water, vortexed for 1 min and spun for 10 min. The resulting upper (lipid) and lower (metabolite) liquid phases were collected separately in 1.5 mL glass vials and dried out in a SpeedVac.

Proteomics {#sec004}
----------

The protein pellet on the bottom was re-suspended in 200 μL 0.5x sample buffer (6X SDS Sample Buffer (0.375M Tris pH 6.8, 12% SDS, 60% glycerol, 0.6M DTT, 0.06% bromophenol blue) transferred to a microcentrifuge tube and dried down to 50 μL in a SpeedVac. The protein samples were loaded on a 4--12% gradient gel (Lonza, \#58520) and ran until the loading dye reached the bottom of the gel. The gel was stained with GELCODE Blue (Fisher Scientific, \#PI24590) for 30 minutes and each lane with sample was cut into 10 equal pieces. Gel sections were reduced with 55 mM dithiothreitol (DTT) (Sigma-Aldrich), alkylated with 10 mM iodoacetamide (Sigma-Aldrich), and digested overnight with TPCK modified trypsin (Promega) at pH = 8.3. Peptides were extracted, dried out in a SpeedVac, re-suspended in 10 μl of 50% ACN, 6% TFA and rocked on a shaker for 15 min. The TiO~2~ TopTip (PolyLC, \# TT10TIO) were washed with 50% ACN, 6% TFA, spin at 1500 rpm 0.5 min for four times. The samples were loaded on the TiO~2~ tips and incubated for 30 min followed by wash with 10 μl 50% ACN, 1% TFA (spin at 1500 rpm 0.5 min), repeated two times, eluted with three times 10 μl 40% ACN, 15% NH~4~OH, added 60 μl buffer A (0.1% formic acid/99.9% water) and dried out to 5 μL. The protein sample was analyzed by positive ion mode LC-MS/MS using LTQ Elite hybrid ion trap-Orbitrap mass spectrometer (Thermo Fisher Scientific) in a data-dependent analysis (DDA Top8). Peptides were delivered and separated using an EASY-nLC nanoflow HPLC (Thermo Fisher Scientific) at 300 nL/min using self-packed 15 cm length × 75 μm i.d. C~18~ fritted microcapillary columns. Solvent gradient conditions were 120 minutes from 3% B buffer to 38% B (B buffer: 100% acetonitrile; A buffer: 0.1% formic acid/99.9% water). MS/MS spectra were analyzed using Mascot search engine v2.5.1 (Matrix Science) by searching the reversed and concatenated Equus caballus (Horse) protein database (UniProt, version 20161102, 20,312 entries) with a parent ion tolerance of 18 ppm and fragment ion tolerance of 0.80 Da. Carbamidomethylation of cysteine (+57.0293 Da) was specified as a fixed modification and oxidation of Methionine (+15.9949), phosphorylation of Serine/Threonine/Tyrosine (+79.97) as variable modifications. Results were imported and analyzed using ScaffoldQ+S 4.6 software (Proteome Software, Inc.) resulting in a peptide false discovery rate (FDR) of \~1%. Further pathway analysis was performed by Panther (<http://www.pantherdb.org/>).

Lipidomics {#sec005}
----------

The dried lipid layer was re-suspended in 30 μL of 1:1 LC/MS grade isopropanol:methanol prior to LC-MS/MS analysis, 5 μL were injected. A Cadenza 150 mm x 2 mm 3 μm C~18~ column (Imtakt) heated to 40°C at 260 μL/min was used with a quaternary pump HPLC with room temperature autosampler (Agilent 1100 series). Lipids were eluted over a 20 min. gradient from 32% B buffer (90% IPA/10% ACN/10 mM ammonium formate/0.1% formic acid) to 97% B. A buffer consisted of 59.9% ACN/40% water/10 mM ammonium formate/0.1% formic acid. Lipids were analyzed using a hybrid QExactive Plus Orbitrap mass spectrometer (Thermo Fisher Scientific) in DDA mode using positive/negative ion polarity switching with 1 MS1 scan followed by 8 MS2 HCD scans per cycle (Top 8). DDA data were acquired from m/z 200--1450 in MS1 mode and the resolution was set to 70,000 for MS1 and 35,000 for MS2. MS1 and MS2 target values were set to 5e5 and 1e6, respectively. Lipidomics data were analyzed using LipidSearch 4.1.9 software (Thermo Fisher Scientific) for identification and validation.

Metabolomics {#sec006}
------------

Half of the metabolite layer was re-suspended in 20 μL LC/MS grade water, 5 μL were injected over a 15 min gradient using a 5500 QTRAP triple quadrupole mass spectrometer (AB/SCIEX) coupled to a Prominence UFLC HPLC system (Shimadzu) via SRM of a total of 287 SRM transitions using positive and negative polarity switching corresponding to 259 unique endogenous water soluble metabolites. Samples were separated using a Amide XBridge HPLC hydrophilic interaction liquid chromatographic (HILIC) column (3.5 μm; 4.6 mm inner diameter (i.d.) × 100 mm length; Waters) at 300 μL/min. Gradients were run starting from 85% buffer B (LC/MS grade acetonitrile) to 40% B from 0--5 min; 40% B to 0% B from 5--16 min; 0% B was held from 16--24 min; 0% B to 85% B from 24--25 min; 85% B was held for 7 min to re-equilibrate the column. Buffer A was comprised of 20 mM ammonium hydroxide/20 mM ammonium acetate (pH = 9.0) in 95:5 water/acetonitrile. Peak areas from the total ion current for each metabolite SRM transition were integrated using MultiQuant version 2.1.1 software (AB/SCIEX). The other half of the metabolite layer was re-suspended in 20 μL LC/MS grade water, 5 μL were analyzed by positive/negative polarity switching mode using a hybrid QExactive HF Orbitrap mass spectrometer (Thermo Fisher Scientific) via a data-dependent analysis (DDA Top8). Metabolites were delivered and separated using an EASY-nLC nanoflow HPLC (Thermo Fisher Scientific) at 225 nL/min using self-packed 15 cm length × 75 μm i.d. C~18~ fritted microcapillary columns. Solvent gradient conditions were 25 minutes from 3% B buffer to 38% B (B buffer: 100% acetonitrile; A buffer: 0.1% formic acid/99.9% water). The data were analyzed using Elements (Proteome Software) with the NIST MS/MS spectral database (<http://chemdata.nist.gov/mass-spc/msms-search/>) and HMDB metabolite database followed by statistical analysis and pathway analysis with Excel 2013 and MetaboAnalyst 3.0 software (<http://www.metaboanalyst.ca/>).

Results and discussion {#sec007}
======================

We utilized a new approach whereby a single aliquot of urine is used for each individual---omics analysis via a liquid-liquid extraction with methyl tert-butyl ether (MTBE). When MTBE, methanol and water are added to urine, the protein precipitates to the bottom while the aqueous polar metabolites form a middle layer and the non-polar lipids form the top layer. Each layer including the protein precipitate was removed and analyzed separately. [Fig 1](#pone.0186258.g001){ref-type="fig"} shows the workflow from the horse anatomy to urine collection, sample preparation, mass spectrometry analysis and the data analysis. The protein mixture was separated into 10 fractions using SDS-PAGE gel \[[@pone.0186258.ref031]\] and in gel digested using trypsin to produce sequenceable peptides. Each peptide mixture was analyzed using a 1hr LC-MS/MS data dependent acquisition (DDA) run with nanoflow HPLC and a hybrid Orbitrap Elite high resolution mass spectrometer in biological triplicates.

![The workflow of the serial-omics analysis of horse urine from collection and MTBE extraction through high resolution tandem mass spectrometry (LC-MS/MS) analysis.\
Each phase of the MTBE extraction is used for either proteomics, metabolomics or lipidomics analyses using untargeted or targeted mass spectrometry in order to gather the---omics profile.](pone.0186258.g001){#pone.0186258.g001}

The results after database searching and interpretation are shown in [Table 1](#pone.0186258.t001){ref-type="table"}. We identified 46 unique proteins and they are ranked according to the number of total peptide spectra identified (spectral count) which can be indicative of relative protein quantity.

10.1371/journal.pone.0186258.t001

###### Equine mare urine proteins identified by LC-MS/MS from a serial-omics liquid-liquid extraction.

![](pone.0186258.t001){#pone.0186258.t001g}

  Protein name                                                                     Accession          MW        \# of spectra
  -------------------------------------------------------------------------------- ------------------ --------- ---------------
  Uromodulin OS = Equus caballus                                                   F7BM54_HORSE       70 kDa    376
  Calcium-activated chloride channel regulator 1 OS = Equus caballus               CLCA1_HORSE        100 kDa   101
  Keratin, type I cytoskeletal 10 OS = Equus caballus                              F6WDW3_HORSE       43 kDa    66
  Protein AMBP OS = Equus caballus                                                 F6UZH0_HORSE       39 kDa    56
  Immmunoglobulin lambda light chain OS = Equus caballus                           F6QAU5_HORSE       11 kDa    47
  Keratin, type II cytoskeletal 1 OS = Equus caballus                              F7B7X0_HORSE       66 kDa    44
  Kininogen-1 OS = Equus caballus                                                  F7C0Z0_HORSE       72 kDa    42
  Keratin, type II cytoskeletal 5 OS = Equus caballus                              F6W7V0_HORSE       62 kDa    33
  Cadherin 1 OS = Equus caballus                                                   F6Y0D9_HORSE       89 kDa    26
  Poly-Ig receptor OS = Equus caballus                                             F6W2K5_HORSE       83 kDa    26
  EGF-containing fibulin-like extracellular matrix protein 1 OS = Equus caballus   F6PVG3_HORSE       55 kDa    25
  Cytokeratin-2e OS = Equus caballus                                               F6SHJ8_HORSE       61 kDa    24
  Pro-epidermal growth factor OS = Equus caballus                                  F7B762_HORSE       133 kDa   23
  Keratin, type II cytoskeletal 6A OS = Equus caballus                             F7AGY4_HORSE       60 kDa    21
  Keratin, type I cytoskeletal 16 OS = Equus caballus                              F6ZEQ3_HORSE       51 kDa    20
  Ubiquitin A-52 residue ribosomal protein fusion product 1 OS = Equus caballus    A0A0B4J1C5_HORSE   15 kDa    19
  Pantetheinase OS = Equus caballus                                                F6Z129_HORSE       58 kDa    17
  Antithrombin protein OS = Equus caballus                                         F7CYR1_HORSE       52 kDa    17
  Trypsinogen OS = Equus caballus                                                  F6VNT7_HORSE       26 kDa    16
  Epithelial cell adhesion molecule OS = Equus caballus                            F6R6Z6_HORSE       33 kDa    16
  Keratin, type II cytoskeletal 73 OS = Equus caballus                             F7C7Y1_HORSE       59 kDa    16
  Cadherin-6 OS = Equus caballus                                                   F6X200_HORSE       88 kDa    14
  Corticosteroid-binding globulin OS = Equus caballus                              F7DRS2_HORSE       45 kDa    14
  Complement C4-A OS = Equus caballus                                              F6XSF7_HORSE       193 kDa   13
  Heparan sulfate proteoglycan 2 OS = Equus caballus                               F7C0I7_HORSE       466 kDa   12
  Butyrophilin-like protein 10 OS = Equus caballus                                 F6VGK4_HORSE       51 kDa    12
  Collagen alpha-3(VI) chain OS = Equus caballus                                   F6R735_HORSE       342 kDa   11
  IgG heavy chain OS = Equus caballus                                              H9GZT5_HORSE       36 kDa    11
  Cadherin-15 OS = Equus caballus                                                  F6WEI6_HORSE       82 kDa    11
  Tenascin-X OS = Equus caballus                                                   F7CCQ6_HORSE       445 kDa   9
  Desmocollin-2 OS = Equus caballus                                                F6UVP2_HORSE       100 kDa   8
  Keratin, type I cytoskeletal 17 OS = Equus caballus                              F6YIA9_HORSE       48 kDa    8
  Mucin-5AC OS = Equus caballus                                                    F6QC83_HORSE       477 kDa   7
  Aminopeptidase N OS = Equus caballus                                             F7B847_HORSE       110 kDa   6
  Major allergen Equ c 1 OS = Equus caballus                                       ALL1_HORSE         22 kDa    6
  Cartilage intermediate layer protein OS = Equus caballus                         F7C2J3_HORSE       133 kDa   5
  Tetratricopeptide repeat protein 28 OS = Equus caballus                          F6WBY4_HORSE       257 kDa   5
  Protein FAM151A OS = Equus caballus                                              F6WIV4_HORSE       64 kDa    4
  Serum albumin OS = Equus caballus                                                ALBU_HORSE         69 kDa    4
  Microtubule-actin cross-linking factor 1 OS = Equus caballus                     F6YMD9_HORSE       827 kDa   3
  Collagen alpha-1 type I chain OS = Equus caballus                                F7A3F7_HORSE       141 kDa   3
  Nuclear receptor co-repressor 2 OS = Equus caballus                              F6UWM2_HORSE       275 kDa   3
  Synapsin-1 isoform Ib OS = Equus caballus                                        F6XVE9_HORSE       58 kDa    3
  AXL receptor tyrosine kinase OS = Equus caballus                                 F6VEV4_HORSE       98 kDa    3
  Nuclear receptor-interacting protein 1 OS = Equus caballus                       F6QWB9_HORSE       127 kDa   3
  Far upstream element-binding protein 2 OS = Equus caballus                       F7A984_HORSE       70 kDa    3

Proteomics is very common for detecting biomarkers, quantifying protein levels across sample conditions and for identifying proteins and post-translational modifications (PTMs) \[[@pone.0186258.ref006], [@pone.0186258.ref032], [@pone.0186258.ref033]\] including urinary proteomics \[[@pone.0186258.ref034]\]. Over 500 proteins were reported from canine urine \[[@pone.0186258.ref035]\], though other articles report far less proteins in mammalian urine \[[@pone.0186258.ref036]\]. For example, one report showed less than 100 proteins in human urine \[[@pone.0186258.ref037]\]. The urinary proteome varies greatly from animal to animal or patient to patient, etc. due to many factors including health, diet, medications, lifestyle, etc. and there is no benchmark of expected numbers. We identified a total of 46 unique proteins from 12 yr old quarter horse mare urine ([Fig 2A and 2B](#pone.0186258.g002){ref-type="fig"}). We required at least 2 unique peptides per protein and a false discovery rate (FDR) of less than 1% for a positive identification from the Uniprot Equus caballus (horse) protein database. The top five proteins other than keratin, a common cytoskeletal protein related to skin and hair, are common to the urinary tract and kidneys and include uromodulin, calcium activated chloride channel protein, protein AMBP, kininogen-1, the cell adhesion cadherin molecules 1, 6, 15 and epithelial cell adhesion molecule, etc. In addition, structural and cytoskeletal proteins were identified as well as other glycoproteins commonly expressed in connective tissue such as tenascin-X. Pantetheinase is secreted from the mucous membranes of the intestine to hydrolyze pantotheine to pantothenate (Vitamin B) (\[[@pone.0186258.ref038], [@pone.0186258.ref039]\]. Butyrophilin-like protein 10 is an intestinal epithelial protein containing an Ig domain and may regulate T lymphocytes \[[@pone.0186258.ref040], [@pone.0186258.ref041]\]. Trypsinogen is a precursor of the enzyme trypsin and is produced in the pancreas and its levels are sometimes used as marker for pancreatitis \[[@pone.0186258.ref042]\]. The corticosteroid-binding globulin protein binds circulating plasma cortisol and may play hormonal roles, possibly in mares, especially during pregnancy when its plasma concentration decreases \[[@pone.0186258.ref043], [@pone.0186258.ref044]\]. The bottom portion of [Fig 2A](#pone.0186258.g002){ref-type="fig"} shows a scatterplot that demonstrates the molecular weight distribution vs relative intensity between lipids, polar metabolites and proteins identified across all LC-MS/MS based---omics experiments from the urine aliquot. These data show that the majority of urinary components are small molecules followed by very large protein molecules and far fewer moderately sized lipids. A detailed description of the [Fig 2B](#pone.0186258.g002){ref-type="fig"} shows a simple number distribution of the various omics results and the bottom portion of [Fig 2B](#pone.0186258.g002){ref-type="fig"} lists a number of topics that we can address using serial-omics. For example, a single aliquot of microliter levels of urine, blood, etc. can be used collect a catalog of molecules from small polar metabolites to non-polar lipids to large proteins and the collection of these molecules may be used to develop biomarkers for tracers of drugs, feed, plants, supplements, etc. in addition to monitoring health or disease status and markers of performance and recovery. However, defining and validating biomarkers of this sort requires the collection and analysis of urine from a large number (\>50) of healthy horses of varying age and gender in order to generate a baseline of "normal" serial-omics profiles \[[@pone.0186258.ref045]\]. However, using targeted mass spectrometry for the quantification of potential biomarkers is a routine and robust approach \[[@pone.0186258.ref046]\].

![**A)** Omics results from the urinary tract and specimen cup to the number of unique molecules identified from horse urine. A scatterplot showing the molecular weight distribution of lipids, metabolites and proteins. Reprinted from The Merck Manual for Pet Health under a CC BY license, with permission from Merck & Co., original copyright 2017. **B)** The ratio of metabolite:protein:lipid was approximately 10.0:1.0:0.22. The majority of urine content is small polar molecules (474) followed by a significant amount of proteins (46) and very low number of lipids (10). A short list of some example questions that can be addressed using a serial-omics approach from accessible bodily fluids such as urine, blood, etc.](pone.0186258.g002){#pone.0186258.g002}

[Fig 3A](#pone.0186258.g003){ref-type="fig"} shows the enriched representative protein pathways using the Panther gene ontology tool \[[@pone.0186258.ref047]\]. Many other proteins were detected in the normal mare urine and are listed in the [S1 Dataset](#pone.0186258.s001){ref-type="supplementary-material"} containing the peptide sequences identified as well as the database search criteria and scoring information.

![Biological pathways represented by serial-omics of healthy horse mare urine.\
**A)** Panther biological processes from proteomics data analysis. **B)** MetaboAnalyst metabolite enrichemnt sets from polar metabolomics data. **C)** The few identified lipids were represented by triglycerides and glycerophospholipids. **D)** Plant metabolites identified as horse diet specific.](pone.0186258.g003){#pone.0186258.g003}

After characterizing the urine proteome of the 12 year old quarter horse mare, we analyzed the aqueous polar metabolite composition of the MTBE extraction middle layer. We used two different approaches to identify small polar metabolites, a targeted method that utilized positive/negative polarity switching via selected reaction monitoring (SRM) \[[@pone.0186258.ref048]\] and an untargeted method using a high resolution QExactive HF mass spectrometer in positive/negative polarity switching mode via DDA using Elements identification software and the NIST small molecule spectral database. From 474 total unique metabolites identified from both experiments in triplicate, the major identifiable pathways are attributable to protein biosynthesis due to an abundance of amino acids likely broken down from hay and grain products. In addition, amino acid related pathways such as methionine, alanine, aspartate, glycine, serine, threonine, arginine and proline metabolism amongst several others are well represented in the metabolome of normal urine. These amino acids are breakdown products from digested proteins in hay and grain as well as amino acids that may be present in feed supplements and not utilized by the horse. In addition, prominent urine and kidney related pathways are well-represented including the urea cycle and ammonia recycling and many other major metabolite pathways such as glutathione metabolism, betaine metabolism, fatty acid oxidation, NAD metabolism, etc.

We then took the top 10 metabolites identified from each experiment (targeted and untargeted) for a total of 20 metabolites and performed a pathway enrichment analysis using MetaboAnalyst software ([Fig 3B](#pone.0186258.g003){ref-type="fig"}) \[[@pone.0186258.ref049]\]. The analysis revealed the major pathways are citric acid cycle, urea cycle, betaine metabolism, taurine and hypotaurine metabolism followed by amino acid metabolism. To better resolve the metabolite analysis, we identified the top 3 most intense metabolites from each metabolomics dataset and characterized them. From the untargeted experiment, hippuric acid, a common carboxylic acid found in the urine of horses and other plant eating species was the most abundant molecule identified followed by creatinine, a breakdown product of creatine that is commonly secreted through urine and is used to monitor normal kidney function and can be used as a urine control metabolite for normalization \[[@pone.0186258.ref050]\]. Phenylacetylglycine was also very abundant and is a gut microbial co-metabolite with hippuric acid and well-studied using LC-MS/MS methods from urine as phospholipidosis markers \[[@pone.0186258.ref051], [@pone.0186258.ref052]\]. p-Cresol glucuronide is another common urine metabolite derived from intestinal bacteria. The targeted SRM based mass spectrometry experiment which is limited to less than 300 metabolites, shows the top molecules as creatinine, betaine, urea, taurine, citrate, etc.; metabolites which are known to be present in high concentrations in urine \[[@pone.0186258.ref004], [@pone.0186258.ref053]\]. The same strategy of taking the top 20 metabolites in MS1 peak intensity from the non-targeted experiment did not yield any known enriched metabolic pathways. The targeted metabolite method can be used to target specific drugs for quantification if one is testing for a particular compound or several compounds \[[@pone.0186258.ref054]--[@pone.0186258.ref057]\]. Our lab routinely performs that test from mouse tumor tissue and there are many reports in urinalysis \[[@pone.0186258.ref058]\]. To name a few more abundant urinary horse metabolites, DOPA sulfate levels in urine have been used to assess central nervous system disorders \[[@pone.0186258.ref059]\] and butyrlcarnitine has been associated with energy metabolism and studied in urine by mass spectrometry for various diseases \[[@pone.0186258.ref060]\]. Although no drugs were administered in the horse, some compounds used mostly as drugs isolated from natural products such as plants were identified. One example is pilocarpine, a glaucoma drug \[[@pone.0186258.ref061], [@pone.0186258.ref062]\]. Since the horse has a plant based diet, it is not unreasonable that some of these compounds may be consumed during pasture grazing. [Table 2](#pone.0186258.t002){ref-type="table"} shows the top 60 metabolites by peak intensity (Top 30 by both targeted and untargeted methods) and the [S2 Dataset](#pone.0186258.s002){ref-type="supplementary-material"} lists all 474 unique identified polar metabolites from both experiments (targeted and untargeted) including peak area quantification and scoring information.

10.1371/journal.pone.0186258.t002

###### Top 60 equine mare urine metabolites by intensity from 474 total identified metabolites by LC-MS/MS from a serial-omics liquid-liquid extraction.

![](pone.0186258.t002){#pone.0186258.t002g}

  ------------------------------------------------------------------- ---------------- ----------------------- -------------------------
  **Polar metabolite name (Untargeted, Top 30)**                      **Accession**    **Molecular Formula**   **MS1 Log10 Peak Area**
  Hippuric acid                                                       HMDB00714        C9H9NO3                 11.8
  Phenylacetylglycine                                                 HMDB00821        C10H11NO3               11.6
  2-Hydroxy-4-trifluoromethyl benzoic acid                            HMDB60715        C8H5F3O3                11.6
  Creatinine                                                          HMDB00562        C4H7N3O                 11.4
  p-Cresol glucuronide                                                HMDB11686        C13H16O7                11.3
  Buntansin A                                                         HMDB35086        C11H 8O5                10.9
  Acetohydroxamic Acid                                                HMDB14691        C2H5NO2                 10.8
  Mesoridazine                                                        HMDB15068        C21H26N2OS2             10.7
  Mammeigin                                                           HMDB30785        C25H24O5                10.6
  Monomethyl phenylphosphonate                                        HMDB31868        C7H9O3P                 10.6
  Neoisoliquiritin                                                    HMDB37317        C21H22O9                10.5
  Geranylgeranylcysteine                                              HMDB11678        C23H37NO3S              10.4
  4-Hydroxy-8-methoxy-2H-furo\[2,3-h\]-1-benzopyran-2-one             HMDB32659        C12H8O5                 10.4
  N\'-Hydroxysaxitoxin                                                HMDB33664        C10H17N7O5              10.4
  4-Hydroxyphenyl-2-propionic acid                                    HMDB41683        C9H10O3                 10.4
  cis-Mulberroside A                                                  HMDB31726        C26H32O14               10.3
  N-Methylphthalimide                                                 CASNO:550-44-7   C9H7NO2                 10.3
  Phlorizin                                                           HMDB36634        C21H24O10               10.3
  L-leucyl-L-proline                                                  HMDB11175        C11H20N2O3              10.2
  Benzocaine                                                          HMDB04992        C9H11NO2                10.2
  Vanilloloside                                                       HMDB32013        C14H20O8                10.2
  apo-\[3-methylcrotonoyl-CoA:carbon-dioxide ligase (ADP-forming)\]   HMDB59607        C7H15N3O2               10.1
  Trimethylamine N-oxide                                              HMDB00925        C3H9NO                  10.1
  Acetaminophen                                                       HMDB01859        C8H9NO2                 10.1
  D-(-)-Isoascorbic acid                                              CASNO:89-65-6    C6H8O6                  10.1
  Butyrylcarnitine                                                    HMDB02013        C11H21NO4               10.1
  DOPA sulfate                                                        HMDB02028        C9H11NO7S               10.0
  Pilocarpine                                                         HMDB15217        C11H16N2O2              10.0
  Pyrogallol-2-O-glucuronide                                          HMDB60017        C12H14O9                10.0
  **Polar metabolite name (Targeted, Top 30)**                        **Accession**    **Molecular Formula**   **Q3 Log10 Peak Area**
  2-Hydroxy-2-methylbutanedioic acid                                  C02612           C5H8O5                  7.7
  citrate                                                             C00158           C6H8O7                  7.3
  2-Isopropylmalic acid                                               C02504           C7H12O5                 7.3
  1-Methyl-Histidine                                                  C01152           C7H11N3O2               7.3
  betaine                                                             C00719           C5H11NO2                7.2
  aconitate                                                           C00417           C6H6O6                  7.1
  oxaloacetate                                                        C00036           C4H4O5                  7.1
  Acetylcarnitine DL                                                  C02571           C9H18NO4                7.1
  allantoin                                                           C01551           C4H6N4O3                7.1
  Urea                                                                C00086           CH4N2O                  6.9
  Acetyllysine                                                        C02727           C8H16N2O3               6.8
  N6-Acetyl-L-lysine                                                  C02727           C8H16N2O3               6.7
  2-hydroxygluterate                                                  C02630           C5H8O5                  6.7
  D-sedoheptulose-1-7-phosphate                                       C05382           C7H15O10P               6.6
  Phenylpropiolic acid                                                HMDB00563        C9H6O2                  6.6
  DL-Pipecolic acid                                                   C00408           C6H11NO2                6.5
  Citraconic acid                                                     C02226           C5H6O4                  6.5
  Ascorbic acid                                                       C00072           C6H8O6                  6.5
  3-hydroxybuteric acid                                               C01089           C4H8O3                  6.5
  Ng,NG-dimethyl-L-arginine                                           C03626           C8H18N4O2               6.3
  Kynurenic acid                                                      C01717           C10H7NO3                6.3
  p-hydroxybenzoate                                                   C00156           C7H6O3                  6.3
  taurine                                                             C00245           C2H7NO3S                6.2
  succinate                                                           C00042           C4H6O4                  6.2
  Aminoadipic acid                                                    C00956           C6H11NO4                6.2
  Atrolactic acid                                                     HMDB00475        C9H10O3                 6.2
  pantothenate                                                        C00864           C9H17NO5                6.1
  2-dehydro-D-gluconate                                               C00629           C6H10O7                 6.1
  orotate                                                             C00295           C5H4N2O4                6.1
  glutamine                                                           C00064           C5H10N2O3               6.1
  ------------------------------------------------------------------- ---------------- ----------------------- -------------------------

In addition to the most abundant metabolites in horse urine, some interesting metabolites were identified that are indicative of the feeding habits of both humans and horses ([Fig 3D](#pone.0186258.g003){ref-type="fig"}). One metabolite, phlorizin, is a common flavonoid metabolite in high concentration in apples, a common treat fed to horses as well as being present in other vegetative plants, leaves, bark, etc. \[[@pone.0186258.ref063]\]. Mammeigin is another common fruit and vegetable specific neoflavinoid compound and may have antiproliferative activity in some cancer cells \[[@pone.0186258.ref064]\]. Buntansin A is a coumerin compound commonly found in plants \[[@pone.0186258.ref065]\]. A surprising finding is that the second most abundant metabolites from the non-targeted metabolomics search was acetohydroxamic acid (AHA), a urea-like molecule that is synthetically made to treat urinary tract infections, prevent kidney stones and studied in human as well as canine urine \[[@pone.0186258.ref066]\]. Since we did not administer this drug to the horse, this may be evidence that AHA is produced naturally in the horse and present in the kidneys and subsequently secreted in the urine. A high level of Monomethyl phenylphosphonate was found to be present and this compound is a breakdown product of leptophos, a no longer used pesticide. It is important to note that Bronco Gold fly spray (Farnum) is routinely used on the horse during summer months during fly season. The main active ingredients in the fly spray are pyrethrins and pyrethroids, piperonyl butoxide and butoxy poly propylene glycol. Many other abundant natural metabolites that do not fit into distinct pathways may be derived from either the feed byproducts or plant derivatives and include N\'-Hydroxysaxitoxin, 4-hydroxyphenyl-2-propionic acid, cis-mulberroside A, neoisoquirtin, etc.

The last---omics component that we analyzed was lipidomics or any identifiable fatty acid containing molecules in the horse mare urine. Urine typically does not contain an appreciable amount of lipid unless nephrotic syndromes are present in either humans or animals \[[@pone.0186258.ref067]\]. A study in human prostate cancer yielded only approximately 100 lipid molecules using LC-MS/MS \[[@pone.0186258.ref068]\]. In general, non-polar lipids should be barely detectable in healthy mammals. We used a QExactive Plus Orbitrap mass spectrometer in polarity switching mode with reversed-phase chromatography with LipidSearch identification software \[[@pone.0186258.ref069], [@pone.0186258.ref070]\]. The results in [Table 3](#pone.0186258.t003){ref-type="table"} and [Fig 3C](#pone.0186258.g003){ref-type="fig"} show that very few lipids were identified. We identified five triglyceride (TG) lipids, two phosphatidic acid (PA) lipids, two phosphatidylethanolamines (PE) and two phosphatidylethanol (PEt) lipids. To put that in perspective, we routinely identify \~1000 lipids or more from cells, plasma, tumors, etc, with our lipidomics platform \[[@pone.0186258.ref008]\]. The fatty acid chains associated with the identified lipid molecules primarily consisted of the basic fatty acid building blocks of palmitate (C16:0), oleate (C18:1) and stearate (C18:0). The very few identified lipids in horse urine are consistent with expectations for a healthy mammal. The [S3 Dataset](#pone.0186258.s003){ref-type="supplementary-material"} contains the detailed lipid search results including scoring information and peak area quantification.

10.1371/journal.pone.0186258.t003

###### Equine mare urine non-polar lipids identified by LC-MS/MS from a serial-omics liquid-liquid extraction.

![](pone.0186258.t003){#pone.0186258.t003g}

  Lipid name               Accession      Ion Formula    MS1 Log10 Peak Area
  ------------------------ -------------- -------------- ---------------------
  PA(16:0/18:1)-H          LMGP10010032   C37H70O8N0P1   7.473
  PA(18:0/18:1)-H          LMGP10010037   C39H74O8N0P1   6.740
  PE(16:0/16:0)+H          LMGP02010037   C37H75O8N1P1   6.842
  PE(18:0/16:0)+H          LMGP02011205   C39H79O8N1P1   6.407
  PEt(16:0/14:0)-H         N/A            C35H68O8N0P1   6.613
  TG(16:0/14:0/16:0)+NH4   LMGL03012786   C49H98O6N1     6.224
  TG(16:0/16:0/16:0)+NH4   LMGL03010001   C51H102O6N1    6.480
  TG(18:0/16:0/16:0)+NH4   LMGL03010004   C53H106O6N1    6.213
  TG(16:0/18:1/18:1)+NH4   LMGL03010100   C55H106O6N1    6.415
  TG(18:1/18:1/18:1)+NH4   LMGL03012612   C57H108O6N1    6.402

Conclusions {#sec008}
===========

It is important to note that the majority of global urine -omics studies have taken place from human and mouse urine samples while most horse urine studies have focused on specific targeted compounds. However, we expect that many mammals should have a somewhat similar urine profile as far as it concerns the major metabolites and proteins. However, diet also plays a crucial role as well as differences in the digestion system between horses and humans. As a result, we found a significant number of plant related metabolites due to a horse's diet of hay and vegetation. As expected, the number of identified proteins (46) from horse mare urine was significant but far less than analyses in other biological tissues such as cells, plasma, solid tissue where thousands of proteins are the norm. The number of small molecule polar metabolites was high with 474 molecules identified. Only 10 non-polar lipid molecules were identified. These show that a single aliquot of horse urine can be used for a liquid-liquid extraction for a multi-omics analysis. We chose to perform lipidomics, proteomics and metabolomics on normal 12 year old horse mare urine. These analyses demonstrate a baseline for omics analyses from horse urine and can be used as a reference for expected future results. This technique can be applied in discovering the presence of a diseased or drug administered-horse from the norm by comparing alterations in the metabolites, lipids and proteins identified. If repeated over a time-course, these analyses can potentially be used to monitor disease progression, health status, inflammation or used to develop biomarkers for performance indicators. Not only do we expect levels of common metabolites and proteins to vary across sample conditions, but unique molecules to be identified in specific cohorts. The proteomic analysis can reveal disease-specific proteins or reveal a relative quantitative change in protein levels. The untargeted metabolomic analyses can identify illicit drug molecules or reveal metabolic changes that indicate disease. In addition, the lipidomics analysis can reveal diseases in the nephrotic system based on the number and types of lipids present. While horses urinate in several liter volumes per episode, we chose to use a very small aliquot of 333 μL in order to demonstrate that we can acquire comprehensive---omics data on small volumes of biological fluid. This can be applied to as little as a few drops of blood, saliva, tears, etc \[[@pone.0186258.ref071]\]. The current state of high resolution tandem mass spectrometry is extraordinarily sensitive down to sub nanogram levels \[[@pone.0186258.ref072]\]. These data represent the first comprehensive multi-omics report from normal and healthy horse urine and is intended to be used as a reference tri-ome for further comprehensive equine urine research. We anticipate follow-up studies will include various equine age groups, sexes, in addition to various time points related to pre and post riding exercises from events such as show jumping, dressage, racing, rodeo, polo, etc.
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###### Proteomics dataset containing all of the identified horse urine proteins from LC-MS/MS analysis and Mascot database searching.

(XLSX)

###### 

Click here for additional data file.

###### Complete polar horse urine metabolomics dataset from both targeted and untargeted LC-MS/MS with polarity switching from Elements database searching.

(XLSX)

###### 

Click here for additional data file.

###### Non-polar horse urine lipidomics dataset from untargeted LC-MS/MS with polarity swiching and LipidSearch database search results.

(XLS)

###### 

Click here for additional data file.
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